What one share of Nautilus Biotechnology holds
On June 9, 2021 (the “Closing Date”), Nautilus Biotechnology, Inc., a Delaware corporation (f/k/a ARYA Sciences Acquisition Corp III (“ARYA”)), consummated the business combination (the “Business Combination”) pursuant to the terms of that certain Business Combination Agreement, dated as of February 7, 2021 (the “Business Combination Agreement”), by and among ARYA, Mako Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of ARYA (“Mako Merger Sub”), and…
Nautilus Biotechnology’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$0.45 |
|---|---|
| Capex (buildings and equipment) | $0.01 |
| Free cash flow | −$0.41 |
| Cash and investments | $0.10 |
| Book value | $1.03 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2020 | — | −$0.54 | $0.03 | −$0.51 | — | −$0.90 |
| 2021 | — | −$0.60 | $0.03 | −$0.49 | — | $2.92 |
| 2022 | — | −$0.46 | $0.02 | −$0.39 | — | $2.52 |
| 2023 | — | −$0.51 | $0.02 | −$0.43 | — | $2.12 |
| 2024 | — | −$0.56 | $0.02 | −$0.49 | — | $1.66 |
| 2025 | — | −$0.47 | $0.01 | −$0.41 | — | $1.24 |
Common questions about Nautilus Biotechnology
How much does one share of Nautilus Biotechnology earn?
Over the last 12 months, Nautilus Biotechnology lost $0.45 for each share.
Does Nautilus Biotechnology pay a dividend?
Nautilus Biotechnology didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is Nautilus Biotechnology’s book value per share?
Nautilus Biotechnology’s book value is $1.03 per share: what would be left for each share if it sold everything at the values on its books and paid every debt, as of June 30, 2026.
How much cash and debt does each share of Nautilus Biotechnology have?
Each share of Nautilus Biotechnology has $0.10 of cash and investments, as of June 30, 2026.
What is Nautilus Biotechnology’s free cash flow per share?
−$0.41 per share over the last 12 months. Free cash flow is the cash left over after spending on buildings and equipment.
Has Nautilus Biotechnology bought back shares?
Nautilus Biotechnology’s share count rose about 334% from 2020 to 2025. That dilution means each share owns a smaller slice of the company.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.